ERBB2 and breast cancer: Moreover, even if HR+/HER2− BC patients generally present lower pCR rates than triple-negative and HER2+ subtypes, the presence of residual disease after neoadjuvant chemotherapy does not necessarily translate to a poor outcome in this BC subtype [58].